KATHMANDU — Drinking more water is generally advised — the common advice is to drink eight glasses per day –and has been associated with better kidney function and a reduced risk of kidney stones.
But drinking an extra four to six extra glasses of water per day won’t slow the decline of kidney functions for chronic kidney disease patients, according to a new study in Britain and Canada.
A study, published in JAMA (Journal of the American Medical Association) by researchers at LaLawson Health Research Institute in Ontario and Western University in London found that coaching patients with Chronic Kidney Disease (CKD) to drink more water does not slow down the decline of their kidney function.
“Despite widespread beliefs, little scientific data exists on the optimal amount of water to drink,” explains Dr. William Clark, Scientist at Lawson and Professor at Western’s Schulich School of Medicine & Dentistry.
“While many claims about the benefits of increased water intake remain untested, a growing body of evidence suggests that increased water intake improves kidney function through the suppression of the antidiuretic hormone.”
Researchers studied whether increased hydration made a difference in people with kidney disease. The clinical trial was published Tuesday in the Journal of the American Medical Association.
The randomized clinical trial included 631 patients at London Health Sciences Center and several other hospitals in Ontario with stage 3 kidney disease from April 2013 to June 2017. At stage 3, patients have lost up to 70 percent of their kidney function.
Half of the participants were coached to drink more water — 1 to 1.5 liters per day, depending on sex and weight. Those in the control group were asked to maintain usual intake or not decrease it by more than one-quarter to a half-liter per day. One liter of water is about 34 fluid ounces.
The researchers, after one year, found the increase of water consumption did not slow the loss of kidney function. They found, however, that the reduction significantly suppressed antidiuretic hormone release, particularly when the participant’s previous intake was low.
“This research indicates that for most patients with CKD, increasing fluid intake will not stop further loss of kidney function. It does allow us then to focus our efforts on other potential therapeutic options,” Clark said.
The researchers hope to conduct another study with a longer followup, according to them.
With Agency InputsFollow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost